CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Peak Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Peak Bio Inc
4900 Hopyard Road, Suite 100
Phone: (925) 463-4800p:925 463-4800 PLEASANTON, CA  94588  United States Ticker: PKBOPKBO
Business Summary
Peak Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on commercializing therapeutics that aim to improve and address unmet medical needs for patients with inflammatory, rare and specialty diseases and cancer. The Company’s lead product candidate, PHP-303, is a small molecule, fifth generation, phase II clinical-ready neutrophil elastase (NE) inhibitor (NEI). PHP-303 is an oral, once daily, 0.65 nanomolar, selective, small molecule reversible inhibitor of NE designed to inhibit its bioactive form that the Company is developing for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder that may result in lung disease or liver disease and, potentially, acute respiratory distress syndrome (ARDS). The Company’s advanced platform in oncology utilizes its toxin, PH-1 or Thailanstatin, to generate a pipeline of antibody-drug-conjugates (ADC) product candidates that are differentiated from traditional ADC-based therapies.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board HoyoungHuh 54 11/1/2022 1/1/2015
Chief Executive Officer, Chief Operating Officer, Company Secretary, Director StephenLamond 61 11/1/2022 3/1/2022
Acting Chief Financial Officer Timothy M.Cunningham 61 11/1/2022 11/1/2022
4 additional Officers and Directors records available in full report.

Business Names
Business Name
IGNY
Ignyte Korea Co, Ltd.
IGNYU
Peak Bio Co., Ltd.
PKBO

General Information
Outstanding Shares: 22,632,843 (As of 2/29/2024)
Shareholders: 131
Stock Exchange: OTC
Federal Tax Id: 852448157
Fax Number: (845) 818-3588


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024